OPEN END TURBO BULL OPTIONSSCHEIN - ASTRAZENECA | Real-time BOERSE MUENCHEN 11:46:56 2024-06-03 EDT | ||
| 2.86 EUR | +5.93% |
|
| 1 month | +5.88% | ||
| 3 months | +513.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 2.86 | +5.93% |
| 24-05-31 | 2.7 | +7.57% |
| 24-05-30 | 2.51 | +5.46% |
| 24-05-29 | 2.38 | -4.03% |
| 24-05-28 | 2.48 | -11.74% |
Real-time BOERSE MUENCHEN
Last update June 03, 2024 at 11:46 am
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HD2SK4 |
| ISIN | DE000HD2SK40 |
| Date issued | 2024-02-19 |
| Strike | 9,925 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.39 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.99 € |
|---|---|
| Lowest since issue | 0.23 € |
| Spread | 0.03 € |
| Spread % | 1.04% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.91%
- Stock Market
- Certificates
- Certificat
